File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Overexpression of AIB1 predicts resistance to chemoradiotherapy and poor prognosis in patients with primary esophageal squamous cell carcinoma.

TitleOverexpression of AIB1 predicts resistance to chemoradiotherapy and poor prognosis in patients with primary esophageal squamous cell carcinoma.
Authors
Issue Date2009
PublisherBlackwell Publishing Japan. The Journal's web site is located at http://www.blackwellpublishing.com/journals/CAS
Citation
Cancer Science, 2009, v. 100 n. 9, p. 1591-1596 How to Cite?
AbstractAIB1 (amplified in breast cancer 1) is frequently overexpressed in esophageal squamous cell carcinoma (ESCC), but the significance of AIB1 expression in chemoradiotherapy (CRT) sensitivity and its effect on prognosis are still unclear. In this study, the expression of AIB1 was examined by immunohistochemistry in 98 biopsy specimens of primary ESCC patients treated with definitive CRT. AIB1 overexpression was found in 63/98 (64.3%) of the ESCCs. There was a significant association between AIB1 overexpression and distant lymph node metastases (P = 0.011), but not regional lymph node metastases. In the M0 subgroup, overexpression of AIB1 was observed more frequently in stage T4 than in stage T2-3 (66.7%vs 38.5%, P = 0.031). In addition, AIB1 expression was the only factor that showed a significant correlation with CRT response, in which overexpression of AIB1 was observed more frequently in the CRT resistant group than in the CRT effective group (86.5%vs 50.8%, P < 0.001). Univariate analysis revealed that AIB1 overexpression was associated with poor progression-free survival (PFS) (P < 0.001) and poor disease-specific survival (DSS) (P <0.001). Furthermore, AIB1 expression could stratify patient survival in stages T2-3, T4, N1, and M0 (P < 0.05), as well as in the CRT effective group (P < 0.05), and AIB1 overexpression and CRT resistance were evaluated as significant independent prognostic factors for both PFS and DSS in multivariate analysis. These findings suggest that overexpression of AIB1 is a useful predictor of CRT resistance and an independent molecular marker of poor prognosis for ESCC patients.
Persistent Identifierhttp://hdl.handle.net/10722/71932
ISSN
2013 Impact Factor: 3.534
2015 SCImago Journal Rankings: 1.744
ISI Accession Number ID
Funding AgencyGrant Number
Major State Basic Research Program of China2006CB910104
863 Project of China2007AA021901
Funding Information:

This study was supported by grants from the Major State Basic Research Program of China (no. 2006CB910104) and the 863 Project of China (no. 2007AA021901).

 

DC FieldValueLanguage
dc.contributor.authorHe, LRen_HK
dc.contributor.authorLiu, MZen_HK
dc.contributor.authorLi, BKen_HK
dc.contributor.authorRao, HLen_HK
dc.contributor.authorDeng, HXen_HK
dc.contributor.authorGuan, XYen_HK
dc.contributor.authorZeng, YXen_HK
dc.contributor.authorXie, Den_HK
dc.date.accessioned2010-09-06T06:36:38Z-
dc.date.available2010-09-06T06:36:38Z-
dc.date.issued2009en_HK
dc.identifier.citationCancer Science, 2009, v. 100 n. 9, p. 1591-1596en_HK
dc.identifier.issn1349-7006en_HK
dc.identifier.urihttp://hdl.handle.net/10722/71932-
dc.description.abstractAIB1 (amplified in breast cancer 1) is frequently overexpressed in esophageal squamous cell carcinoma (ESCC), but the significance of AIB1 expression in chemoradiotherapy (CRT) sensitivity and its effect on prognosis are still unclear. In this study, the expression of AIB1 was examined by immunohistochemistry in 98 biopsy specimens of primary ESCC patients treated with definitive CRT. AIB1 overexpression was found in 63/98 (64.3%) of the ESCCs. There was a significant association between AIB1 overexpression and distant lymph node metastases (P = 0.011), but not regional lymph node metastases. In the M0 subgroup, overexpression of AIB1 was observed more frequently in stage T4 than in stage T2-3 (66.7%vs 38.5%, P = 0.031). In addition, AIB1 expression was the only factor that showed a significant correlation with CRT response, in which overexpression of AIB1 was observed more frequently in the CRT resistant group than in the CRT effective group (86.5%vs 50.8%, P < 0.001). Univariate analysis revealed that AIB1 overexpression was associated with poor progression-free survival (PFS) (P < 0.001) and poor disease-specific survival (DSS) (P <0.001). Furthermore, AIB1 expression could stratify patient survival in stages T2-3, T4, N1, and M0 (P < 0.05), as well as in the CRT effective group (P < 0.05), and AIB1 overexpression and CRT resistance were evaluated as significant independent prognostic factors for both PFS and DSS in multivariate analysis. These findings suggest that overexpression of AIB1 is a useful predictor of CRT resistance and an independent molecular marker of poor prognosis for ESCC patients.en_HK
dc.languageengen_HK
dc.publisherBlackwell Publishing Japan. The Journal's web site is located at http://www.blackwellpublishing.com/journals/CASen_HK
dc.relation.ispartofCancer scienceen_HK
dc.rightsThe definitive version is available at www.blackwell-synergy.com-
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols - therapeutic use-
dc.subject.meshCarcinoma, Squamous Cell - drug therapy - metabolism - radiotherapy - secondary - therapy-
dc.subject.meshDrug Resistance, Neoplasm-
dc.subject.meshEsophageal Neoplasms - drug therapy - metabolism - pathology - radiotherapy - therapy-
dc.subject.meshHistone Acetyltransferases - metabolism-
dc.titleOverexpression of AIB1 predicts resistance to chemoradiotherapy and poor prognosis in patients with primary esophageal squamous cell carcinoma.en_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1347-9032&volume=100&issue=9&spage=1591&epage=1596&date=2009&atitle=Overexpression+of+AIB1+predicts+resistance+to+chemoradiotherapy+and+poor+prognosis+in+patients+with+primary+esophageal+squamous+cell+carcinomaen_HK
dc.identifier.emailGuan, XY:xyguan@hkucc.hku.hken_HK
dc.identifier.authorityGuan, XY=rp00454en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1111/j.1349-7006.2009.01224.xen_HK
dc.identifier.pmid19552757-
dc.identifier.scopuseid_2-s2.0-70149102417en_HK
dc.identifier.hkuros166056en_HK
dc.identifier.volume100en_HK
dc.identifier.issue9en_HK
dc.identifier.spage1591en_HK
dc.identifier.epage1596en_HK
dc.identifier.isiWOS:000268923800006-
dc.identifier.scopusauthoridHe, LR=35069492500en_HK
dc.identifier.scopusauthoridLiu, MZ=35285929300en_HK
dc.identifier.scopusauthoridLi, BK=26663761000en_HK
dc.identifier.scopusauthoridRao, HL=35277843000en_HK
dc.identifier.scopusauthoridDeng, HX=24079601100en_HK
dc.identifier.scopusauthoridGuan, XY=7201463221en_HK
dc.identifier.scopusauthoridZeng, YX=7402981579en_HK
dc.identifier.scopusauthoridXie, D=35070710200en_HK
dc.identifier.citeulike5445300-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats